Real-time Stock quotes, portfolio, LIVE TV and more.
Dec 14, 2010, 05.21 PM IST
In an interview with CNBC-TV18, Mahendra Patel, MD, Lincoln Pharmaceuticals, spoke about the latest happenings in his company and sector.
Here is the verbatim transcript of his interview with CNBC-TV18's Ekta Batra and Reema Tendulkar. Also watch the accompanying video.
Q: Could you tell us about this tie up that have done with US based HBI? What will it do in terms of the revenues for the company?
A: This is a wound care product, basically it is biotech product. It is produced from collagen and it is prepared in shape of patches and granules. So, it can be majorly used in wound care, burns and any type of wounds. This is very unique product and gives good result to the patient.
With this product we will be a larger player in wound care treatment. Presently, one or two companies are there, but our product is good. We aim that more than 80% stake of wound care we will receive by this product.
Q: No doubt the tie up will help the patients, but for the company per se, what is the kind of revenue accretion that you see, when will you start marketing these products in India, will it happen this year and what will be the revenue accretion on account of this?
A: Revenue point of view we will add nearly 10% of the turnover. It is a high profitable product, but we are not aiming more profit. Revenue wise it is a 10% addition to the company.
Q: Could you go through what the structure of this particular deal was? Did you receive any sort of milestone payments at all etc and what exactly is the revenue share going forward be?
A: For this deal, presently we are importing from US and we are marketing this product and slowly we will start manufacturing in India. We joined hands with Human Bioscience, so in second phase it will be manufactured in India. But in the first phase the product is imported from US and we will distribute and market in India. This is the system which we have designed.
Q: You launched the Caroverine injection in India and a very niche product which you have launched. How exactly are you doing in terms of revenues and what sort of scale up are you seeing within this particular drug?
A: This Caroverine is a very new product and it is first time in India. So, particular revenue we will not able to tell you the exact figure, but definitely there is no player. So, we will capture a big market in this area because there are number of patients, but there is no medicine. So, in terms of revenue we consider that at least 12-15% revenue we will add in this product. But it will increase very fast because there is only one product that is our product is available in the market now. So, this is our goal for this product.
May 20 2013, 15:05
- in MARKET OUTLOOK
May 20 2013, 12:21
- in Commodities